vs
Side-by-side financial comparison of Perella Weinberg Partners (PWP) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $219.2M, roughly 1.4× Perella Weinberg Partners). Bio-Techne runs the higher net margin — 12.8% vs 6.3%, a 6.6% gap on every dollar of revenue. On growth, Perella Weinberg Partners posted the faster year-over-year revenue change (-2.9% vs -6.4%). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 4.2%).
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
PWP vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $219.2M | $295.9M |
| Net Profit | $13.8M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 8.5% | 18.4% |
| Net Margin | 6.3% | 12.8% |
| Revenue YoY | -2.9% | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | $0.11 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $219.2M | $295.9M | ||
| Q3 25 | $164.6M | — | ||
| Q2 25 | $155.3M | $317.0M | ||
| Q1 25 | $211.8M | $316.2M | ||
| Q4 24 | $225.7M | $297.0M | ||
| Q3 24 | $278.2M | $289.5M | ||
| Q2 24 | $272.0M | $306.1M | ||
| Q1 24 | $102.1M | $303.4M |
| Q4 25 | $13.8M | $38.0M | ||
| Q3 25 | $6.0M | — | ||
| Q2 25 | $2.7M | $-17.7M | ||
| Q1 25 | $17.3M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $16.4M | $33.6M | ||
| Q2 24 | $-66.0M | $40.6M | ||
| Q1 24 | $-35.8M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 8.5% | 18.4% | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 5.8% | -7.5% | ||
| Q1 25 | 5.5% | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | 12.9% | 13.8% | ||
| Q2 24 | -30.2% | 15.0% | ||
| Q1 24 | -52.4% | 22.1% |
| Q4 25 | 6.3% | 12.8% | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 1.8% | -5.6% | ||
| Q1 25 | 8.2% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 5.9% | 11.6% | ||
| Q2 24 | -24.3% | 13.3% | ||
| Q1 24 | -35.1% | 16.2% |
| Q4 25 | $0.11 | $0.24 | ||
| Q3 25 | $0.08 | — | ||
| Q2 25 | $0.04 | $-0.11 | ||
| Q1 25 | $0.24 | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | $0.24 | $0.21 | ||
| Q2 24 | $-1.21 | $0.26 | ||
| Q1 24 | $-0.91 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $255.9M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $-127.4M | $2.0B |
| Total Assets | $797.6M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $255.9M | $172.9M | ||
| Q3 25 | $185.5M | — | ||
| Q2 25 | $145.0M | $162.2M | ||
| Q1 25 | $111.2M | $140.7M | ||
| Q4 24 | $407.4M | $177.5M | ||
| Q3 24 | $335.1M | $187.5M | ||
| Q2 24 | $185.3M | $152.9M | ||
| Q1 24 | $156.7M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $-127.4M | $2.0B | ||
| Q3 25 | $-302.4M | — | ||
| Q2 25 | $-318.4M | $1.9B | ||
| Q1 25 | $-323.1M | $2.0B | ||
| Q4 24 | $-421.4M | $2.1B | ||
| Q3 24 | $-360.8M | $2.1B | ||
| Q2 24 | $-283.0M | $2.1B | ||
| Q1 24 | $161.9M | $2.0B |
| Q4 25 | $797.6M | $2.5B | ||
| Q3 25 | $650.2M | — | ||
| Q2 25 | $606.7M | $2.6B | ||
| Q1 25 | $570.5M | $2.6B | ||
| Q4 24 | $876.8M | $2.7B | ||
| Q3 24 | $810.9M | $2.7B | ||
| Q2 24 | $645.5M | $2.7B | ||
| Q1 24 | $583.6M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.8M | — |
| Free Cash FlowOCF − Capex | $30.5M | — |
| FCF MarginFCF / Revenue | 13.9% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | 2.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-34.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.8M | — | ||
| Q3 25 | $59.2M | — | ||
| Q2 25 | $56.1M | $98.2M | ||
| Q1 25 | $-176.5M | $41.1M | ||
| Q4 24 | $223.4M | $84.3M | ||
| Q3 24 | $200.3M | $63.9M | ||
| Q2 24 | $90.0M | $75.5M | ||
| Q1 24 | $-206.3M | $81.0M |
| Q4 25 | $30.5M | — | ||
| Q3 25 | $57.6M | — | ||
| Q2 25 | $55.3M | $93.3M | ||
| Q1 25 | $-177.6M | $31.0M | ||
| Q4 24 | $207.0M | $77.5M | ||
| Q3 24 | $199.3M | $54.7M | ||
| Q2 24 | $83.7M | $57.5M | ||
| Q1 24 | $-214.8M | $64.5M |
| Q4 25 | 13.9% | — | ||
| Q3 25 | 35.0% | — | ||
| Q2 25 | 35.6% | 29.4% | ||
| Q1 25 | -83.8% | 9.8% | ||
| Q4 24 | 91.7% | 26.1% | ||
| Q3 24 | 71.6% | 18.9% | ||
| Q2 24 | 30.8% | 18.8% | ||
| Q1 24 | -210.3% | 21.3% |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.5% | 1.5% | ||
| Q1 25 | 0.5% | 3.2% | ||
| Q4 24 | 7.3% | 2.3% | ||
| Q3 24 | 0.4% | 3.2% | ||
| Q2 24 | 2.3% | 5.9% | ||
| Q1 24 | 8.3% | 5.4% |
| Q4 25 | 2.52× | — | ||
| Q3 25 | 9.85× | — | ||
| Q2 25 | 20.50× | — | ||
| Q1 25 | -10.18× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 12.23× | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PWP
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
